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Background: Since the “War on Cancer” was declared in 1971, the United States alone has expended some $300
billion on research, with a heavy focus on the role of genomics in anticancer therapy. Voluminous data have been
collected and analyzed. However, in hindsight, any achievements made have not been realized in clinical practice
in terms of overall survival or quality of life extended. This might be justified because cancer is not one disease but
a conglomeration of multiple diseases, with widespread heterogeneity even within a single tumor type.
Discussion: Only a few types of cancer have been described that are associated with one major signaling pathway.
This enabled the initial successful deployment of targeted therapy for such cancers. However, soon after this
targeted approach was initiated, it was subverted as cancer cells learned and reacted to the initial treatments,
oftentimes rendering the treatment less effective or even completely ineffective. During the past 30 plus years, the
cancer classification used had, as its primary aim, the facilitation of communication and the exchange of
information amongst those caring for cancer patients with the end goal of establishing a standardized approach for
the diagnosis and treatment of cancers. This approach should be modified based on the recent research to affect a
change from a service-based to an outcome-based approach. The vision of achieving long-term control and/or
eradicating or curing cancer is far from being realized, but not impossible. In order to meet the challenges in
getting there, any newly proposed anticancer strategy must integrate a personalized treatment outcome approach.
This concept is predicated on tumor- and patient-associated variables, combined with an individualized response
assessment strategy for therapy modification as suggested by the patient’s own results. As combined strategies
may be outcome-orientated and integrate tumor-, patient- as well as cancer-preventive variables, this approach is
likely to result in an optimized anticancer strategy.
Summary: Herein, we introduce such an anticancer strategy for all cancer patients, experts, and organizations:
Imagine a World without Cancer.
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Recently, Kohane stated that “the size and complexity
of needed multidimensional characterization of patients
will lead to far more complex diagnostic and prognostic
categories than are currently in use” [1]. The end result
of this concept is an improved ability to understand in-
teractions between macro-and micro- tumor environments.
Ultimately, this may allow us to precisely characterize
patients by more components, dig deeper and classify
each patient by variations of the individual organ, gene,
and even, molecular make-up [1]. Applying this to cancer,
the vision of eradicating and/or curing cancer is far from
being realized. Meeting this goal in the future, however,
requires an approach that should not be focused solely on
genotyping. Rather, the future of oncology will have to in-
tegrate the increasing power of information achieved by
research into rapidly adaptable anticancer treatment
strategies. Imagine a World without Cancer is clearly a
goal of all cancer patients, experts and organizations,
and this requires a focused anticancer strategy that cul-
minates in a personalized treatment strategy based on a
new cancer classification scheme combined with an as-
sessment of the individualized patient response for therapy
modification (Figure 1). Combining both strategies should
result in a disease-focused, outcomes-based approach that
integrates tumor- and patient-specific variables, where
both basic and clinical research results are united in a
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Where we are - current status of war on cancer
The oldest case of a metastatic cancer case was found in
the skeleton of a 2,700 year old male in Siberia, Russia
[2] while and the oldest cancer description (1,500 BCE)
was discovered in Egypt within the so-called Edwin Smith
Papyrus [3,4]. The term cancer is derived from the Greek
word for crab, Karkinos, coined by Hippocrates (460–370
BC). Cancer stands for a malignant tumor, one that is
characterized by anaplasia (i.e., the loss of normal ap-
pearance of cells) and autonomy (loss of inhibition of
growth) displaying invasive and tissue-destroying proper-
ties [5]. Approximately 130 years ago, a Russian student
in the Veterinary Department of the Medical Surgery
Academy in St. Petersburg, Mistislas Aleksandrovich
Novinsky (1841–1914), obtained a dog with a carcinoma
of the nose and transplanted small fragments subcutane-
ously into a healthy puppy, thereby demonstrating growth
of the transplanted tumor mass [5,6].
The War on Cancer was declared by President Nixon
in1971 when he signed the National Cancer Act, with
the primary aim of strengthening the National Cancer
Institute (NCI). Since then, the US alone has expended
billions on huge data collection and analyses, under-
standing genomic techniques, and on anticancer treat-
ments. From a “birds-eye” view, it may appear that we
have made little progress in eradicating cancer and that
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most exclusively on those therapies that demonstrate
statistical significance without carefully evaluating if
the patient’s quality of life has improved or whether the
overall survival represents a meaningful period - not
just simply calculating survival in weeks or months.
Thus, we may have relied too heavily on the worship of
false gods, and not selected our metrics properly.
Since Novinsky’s experiment in 1876, cancer has been
classified, structured, and sub-grouped the tissues of ori-
gin (organ-based cancer classification) by tumor size (T),
by lymph node involvement (N), and spread to organs (M).
This TNM classification of Malignant Tumors (TNM) has
been used by both the International Union Against Cancer
(UICC) and the American Joint Committee on Cancer
(AJCC) and is presented in the 7th edition of the UICC
and AJCC Cancer Staging Manual [7], where it forms the
basis for treating cancer patients. Problems do exist: un-
necessary invasive diagnostic tests (angiography, diagnostic
laparoscopy/laparotomy, mammograms, prostate biopsies,
etc.), over-treatment (radiation exposure), and vast over-
utilization of medical resources occur; and yet, many still
experience misdiagnosis or, at best, a penurious extension
in life (though not necessarily an improved quality of life in
the extended survival). Improvements need to occur, and
soon, but are easier said than done.
Pathologic staging can have mistakes: tissue can be
sampled incorrectly or in inadequate amounts relative to
the likely tumor mass by different variables: the person
who maintains the biopsy/specimen, the investigator, or
the evaluation of the pathologist. If cancerous cells are
not present within the slide or image, an absence of
cancer may be concluded with serious or even fatal con-
sequences for the patient. Additionally, not identifying
small numbers of cancerous cells intermixed with healthy
cells on one slide can also occur. Moreover, some types of
cancer (i.e., brain and spinal cord) are graded by matching
the cell type, while others such as blood, bone marrow
and lymphomas are classified by phenotype or a combin-
ation of location and symptoms (i.e., Ann Arbor classifica-
tion of lymphomas from 1971) [8]. Yet this results largely
in broad classifications of tumors, which to the best of our
current understanding may act quite differently on a
biological level. An attempt to account for the biological
behavior and prognostic relevance of certain tumors is
reflected by grade and bulk as introduced by the Cots-
wold modification [9].
Another undefined point is the number of biopsy sam-
ples that optimally should be collected for making a
diagnosis with a high probability of being correct. It has
been shown that biopsies that are not guided by a 3-D
imaging approach of a suspect lesion have odds of detec-
tion that are far lower than a clinician might expect [10].
For example, if a cancer is limited to ~5% in all threedimensions and the tissue or organ volume is consid-
ered, the odds of finding the cancer through standard bi-
opsy techniques are less than 50%. Translating this to a
run-of-the-mill prostate carcinoma, the number of tissue
samples would have to be approximately 18–20 ran-
domly collected biopsy specimens. When compared to
the usual > 8 biopsies most patients receive, this could
increase the odds of finding a potential cancerous lesion
to 90-95%.
Cancer is not a single disease
Although often used in the singular, cancer is not one
disease, but rather a collection of more than 100 diseases
with some traits in common [11]. There are but a few
cases of cancer that have been associated with important
signaling pathway (e.g. Bcr-Abl tyrosine kinase in chronic
myelogenous leukemia, CML), which has allowed for the
deployment of targeted therapy [12]. However, we soon
learned, empirically, that this targeted therapeutic ap-
proach was subverted over time as the cancer cells
learned and reacted to the initial treatment, oftentimes
rendering the treatment less effective or completely in-
effective. As one example, consider Bcr-Abl and its role
in CML. Point mutations exist on at least 13 different
amino acids distributed over the Abl-kinase domain,
which make it difficult to overcome drug resistance. How-
ever, once that threshold of drug resistance is reached, the
patient usually succumbs to the cancer as the therapy is
rendered ineffective [12,13].
It is important to understand that the existing cancer
classification scheme was originally intended to facilitate
communication and exchange information among phy-
sicians and oncologists. This was necessary for both a
widely accepted cancer classification system and for
standardizing anticancer therapy over the past half cen-
tury. The change in cancer incidences as well as the
achievements have been pointed out recently within the
Blueprint of the American Society of Clinical Oncology
(ASCO): “Two out of three people live at least five years
after cancer diagnosis, up from roughly one out of two
in the 1970s” and “The nation’s cancer death rate has
dropped 18 percent since the early 1990s, reversing decades
of increases” [14,15]. Although cancer survival rates have
improved over the past several decades [16], this can be
attributed to larger gains in some cancers including breast,
colon, and Hodgkin’s lymphoma, while improvements in
survival may (at best) be of barely a few weeks for cancers
of the lung, brain, or pancreas [17]. We would argue that
many of the gains in cancer therapy have come at the cost
of quality of life in cancer survivors, a fact not often in-
corporated in the statistics. Perhaps by shifting our
focus from the killing of cancer cells to merely delaying
the ability of cancers to cause illness might yield better
results both in prognosis and, importantly, in quality of
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examining the basic biochemical lesions associated with
cancer.
The necessity of including patient- and tumor-associated
variables to a modified cancer classification
Will the recent developments in molecular science and,
where feasible, surgery to remove the cancer mass cure
cancer alone? Hanahan & Weinberg focused on the six
biological processes “during the multi-step development
of human tumors: sustaining proliferative signaling, evading
growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activation inva-
sion, and metastasis” [18]. On the other hand, Vogelstein
and Kinzler [19] proposed that cancer is a disease that is
the result of damage to the DNA with consecutive genetic
mutations. Therefore, it has been proposed to include mo-
lecular information into traditional classifications such as
in many solid cancers. Unfortunately, this information is
not yet fully understood and not routinely applied in clin-
ical practice due to the absence of standardized criteria
and/or research funding [20].
The inclusion of findings in Genomics/Epigenomics,
Metabolomics, Proteomics, Inflammation, Immunology,
Adult Stem Cell research as well as response informa-
tion to the traditional histopathological staging and to
patient-associated variables (such as risk calculation pro-
files, life quality and psychosomatic/spiritual profiling)
seems not only important, but also necessary. Jones and
Baylin revealed that genetics and epigenetics cooperate
at all stages of carcinogenesis, and “that epigenetic abnor-
malities in cancer comprise a multitude of aberrations in
virtually every component of chromatin involved in pack-
aging the human genome” [21]. One molecular approach
or signaling pathway will not determine the future needs
of a cancer therapy that is biologically-oriented and classi-
fied, and dictates both treatment and prevention.
Several examples currently exist of an attempt to bridge
the molecular changes with treatment, prognosis and out-
come. Investigating the TGF-beta1signal transduction re-
vealed that the amplification of the ski-gene, a repressor
of TGF-beta1, correlates with significantly worse survival
outcomes in colon carcinoma [22]. Moreover deletions in
smad4 and smad7 correspond with worse prognosis in
chemotherapy-treated colon carcinoma [23,24]. Adding
Cetuximab (Erbitux; ImClone Systems Inc.), a monoclonal
antibody and inhibitor of EGFR, to multimodal treatment
increased efficiency of anticancer therapy in patients with
k-RAS wild type non-resectable liver metastasis originally
from colorectal carcinoma (CRC) [25]. The complexity of
molecular profiling can be seen by the example of adding
predictive response information by genotype-wide single
nucleotide polymorphisms (SNPs) screening. It was shown
that SNPs in patients homozygous for the wild type allelesof LIFR rs3729740 undergoing treatment with Cetuximab
(Erbitux; ImClone Systems Inc.) and possibly ANXA11
rs1049550 in those patients receiving Bevacizumab
(Avastin; Genentech Inc.) can serve as markers for che-
mosensitivity to multimodal treatment [26]. Additionally,
this was also shown in a recent study in the setting of
metastatic colorectal cancer [27]. The increase in molecu-
lar profiling through metabolic phenotyping will likely
generate patient-specific information on tumor biology,
allowing physicians to improve diagnostic capabilities and
helping to select the appropriate optimized treatment
for that individual tumor in that particular patient [28].
Further categorization has been demonstrated in blad-
der cancer research, where adding epigenetic mecha-
nisms such as DNA-methylation, histone-modification
and ncRNA-expression may result in future potential
biomarkers and/or therapeutic targets [29].
In the field of cancer metabolics, the Warburg effect,
defined by an increased utilization of glucose via glycoly-
sis, is a common biochemical characteristic of cancerous
cells [30]. Proliferating cells have intrinsic increased meta-
bolic activities compared to non-proliferating cells [31].
These findings have been clinically addressed earlier, by
differentiating cancer patients into metabolic responders
and non-responders [32]. An adverse regulator of the
Warburg effect, suppressing tumor growth in vivo, has
also been recently reported [33]. By preventing or slow-
ing the loss of contact inhibition, whereby cancer cells
become aware of their neighboring cells and do not run
rampant across the geography of a tissue or organ, we
can decrease the onset or progression of pathology,
organ dysfunction, disease, and death. This approach
would support a strategy to develop methods for further
analyzing the signaling networks that underlie cancer
development, progression, and drug resistance [34].
Another important field in basic cancer research with
future impact in personalized oncology is investigating
proteins on their structure and function or proteomics.
The potential achievements of the Human Proteome
Project, a collaboration investigating the complete in-
dividual protein information, were reviewed recently
[35]. The primary aim of this work is to enable a better
understanding of how cancer cells thrive in their envir-
onment [35,36]. Future contributing results might be
expected on serum-based algorithms stratifying anti-
cancer therapy [37].
Different types of inflammation can have also an effect
on initiation, promotion or progression of tumor devel-
opment [38]. As the function of the stroma in the tumor
microenvironment has been underestimated for many
years, it has been reported that stromal cell-related cyto-
kines of inflammation such as tumor necrosis factor
alpha (TNF-α) activate nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) play important but
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For example, suppression of NF-κB by anti-TNF-α leads
to an inhibition of disease progression in hepatocellular
carcinoma [40]. The association of tumor-infiltrating
T-cells and their well-defined correlation with clinical
outcomes in ovarian, breast, prostate, renal, esophageal,
colorectal carcinomas, and melanomas were cardinal ob-
servations in the understanding of the role that immun-
ology plays in cancer [41-47]. Inflammation, as well as the
tumor environment, interacts in all different types of im-
mune cells [38]. The clinical findings of immuno-oncology
in prostate cancer and melanoma have resulted in signifi-
cant contributions in the struggle against cancer with the
least adverse effects of any known cancer therapy cur-
rently in use [48,49].
The Nobel-Prize winning discovery of pluripotency,
demonstrated by Shinya Yamanaka in 2006, wherein a
differentiated cell altered into an induced pluripotent
stem cell by a defined set of transcription factors has
opened up another potentially lucrative therapeutic ap-
proach against cancer [50,51]. All these approaches viewed
collectively and applied judiciously can prevent the known
obstacles of drug resistance, evolution of alternate paths of
tumorigenesis, cytotoxicity and, importantly, improve the
quality of life for cancer patients.
Non-traditional aspects of care
There are other potential targets of cancer that extend
beyond the traditional boundaries of anti-cancer therapy.
Calculating the personal risk for patient outcome comes
into sharper focus, since it has been shown that there is
a generational shift in metabolic risk factors [52], which
will influence future generations in life expectancy, com-
bined with co-morbidities and in quality in life (QL). A
Cochrane analysis assessing the effects of psychosocial
interventions for an improvement of QL revealed that
it can be “concluded, that nurse-delivered interventions
comprising information combined with supportive at-
tention may have a beneficial impact on mood in an
undifferentiated population of newly diagnosed cancer
patients” [53]. Although assumed to exist for some time
now no correlation was observed until recently that sym-
pathetic activation, triggered by prolonged emotional
stress affects overall survival, tumor incidence, shorter sur-
vival, and perhaps, increased recurrence of breast cancer
and metastasis [54,55]. More recently it has been shown
in a mouse model that the stimulatory effect of sympa-
thetic activation on bone metastasis can be blocked with
a beta-blocker or by inhibiting RANKL signaling in can-
cer cells. It follows that this might explain the reduced
survival rate of breast cancer patients experiencing se-
vere depression and serves as one potential focus point
in the future to use beta-blockers as an adjuvant therapy
for women with breast cancer [56]. Potential variablesinclude other future scientific information, e.g., spiritual
care [57] and their compilation with their biological
targets.
Patient response
Despite these improvement, cancer patients more often
present with locally advanced tumor categories (cT3/4)
such that only about 30% of patients undergoing primary
surgery will typically have microscopically R0 resections
performed [58,59]. Therefore, a multi-modal approach
has been under investigation for the past 40-plus years
[60] with the aim of increasing the local-regional tumor
control by an increase in the proportion of radical tumor
resections where the boundaries of the tumor can be de-
fined. Concepts of down-staging and increasing the abil-
ity to achieve negative tumor margins through the use of
a multimodal therapy approach in a neoadjuvant setting
have infiltrated the everyday care of cancer patients.
Therefore, patient response criteria in evaluating the
effect of anti-cancer therapy [61-63] need to be revisited
[64]. These new criteria must include not just statisti-
cally significant overall survival rates of a few weeks/
months or selecting few genetic markers, but must also
consider findings in basic laboratory tests, histopath-
ology, biochemistry, imaging, quality of the patient’s life
post-treatment as well as psychosomatic areas. All of
these truly define the care for the cancer patient, and
require investigative changes implemented during multi-
modal treatment. Although we know that responders
have better tumor biology, health outcomes, and a good
prognosis, no significant therapeutic consequences or
patient management trials using this biochemically fo-
cused, lesion-altering approach have been reported to
date [64] with one exception [65].
Prevention
According to the National Cancer Institute, prevention
is “the reduction of cancer mortality via reduction in the
incidence of cancer” [66]. Both models of carcinogenesis,
the one from Vogelstein and Kinzler [19,67] and the one
from Hanahan and Weinberg [68], which have been
mentioned above, include the influence of risk factors
with negative influence and those with positive prevent-
ive effects. Accomplishments in clinical research have
included looking at changes in lifestyle, reducing risk
factors, preventing infections (which contribute to about
18% of all cancer causes) [69], improving dietary intake,
as well as incorporating molecular biology. Only by un-
derstanding the complete pathway of carcinogenesis
that includes variables such as biology and tumor me-
tabolism, along with incorporating new ways of medical
therapy (chemoprevention) modifying cancer-causing
factors, and better identifying those with genetic predis-
positions for cancer will be able to make a dramatic leap
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tection is an oft-used phrase which should be common-
place—buoyed by improvements in laboratory, radiogra
phic, endoscopic tests and physical examinations. In reality,
using biomarkers for the diagnosis of cancer in early
tumor stages where a higher chance of cure is possible,
or improved access to screening programs, is still lacking.
Even one of the most widely used screening programs,
PSA for prostate cancer, has failed, clearly illustrating the
difference between the wishes of scientists and reality in
the clinic [70].
Although a multi-billion ‘nutrition’ market has evolved
with the primary aim of lessening exposure to cancer-
promoting agents and improving host defense mecha-
nisms, this has so far not provided evidence that this
nutritional supplements lead to a decrease of the indi-
vidual cancer risk [71]. Furthermore, it does not seem
clear why this failure to greatly impact cancer rates oc-
curs. Is this a dosing issue? Or is it that the nutrients
themselves do not help? A large-scale study revealed an
inverse relation between selenium intake, and reduc-
tion of prostate risk, as it was shown in a Dutch cohort
trial [72].
Already in clinical use is a cancer prevention strategy:
the elimination of precancerous lesions by colonoscopy
for colorectal polyps, but its increasing use without a
proven concept and leading to enormous health costs
had recently been called into question [73].
Summary
Joining forces
Widespread anti-cancer therapy may be more success-
fully accomplished for patients through joining forces of
all the aspects discussed here. Combining a renewed
focus on a cancer classification which includes not just
histomorphological organ-specific variables as size, lymph
node and/or distant tumor spread. We concede that this
was necessary in the past and these significant achieve-
ments in anticancer therapy lead to standardization as well
as they made it possible, that results had been comprehen-
sible worldwide. This has been one major basis for the
achievements in the War on Cancer. With the increased
molecular and biocomputional information and under-
standing of all different cancer research disciplines, now
might be the time to pivot to a combination of a person-
alized and an individualized diagnosis and treatment
strategy. Such a personalized strategy could integrate all
necessary different patient- and tumor-associated variables
with the consecutive stratification of anticancer-treatment.
Despite a straight forward orientated prevention strategy,
the combination with patient- and tumor-associated vari-
ables in terms of response to anticancer treatment could
result in the necessary modification of the stratified anti-
cancer treatment. For that, such a strategy would be ofenormous practical use to the clinician as well as for the
research community, joining forces more effectively.
The effects of such a combined strategy (Figure 1)
could be:
1. a tumor- and patient-orientated predictive cancer-
staging system with the stratification of different
forms of personalized therapy and
2. the development of a standardized multivariable
response evaluation system with the consequence of
future standardized therapy modifications
(individualized cancer strategy).
”Imaging A World Without Cancer“ is clearly a vision.
For its realization, a global personalized and individual-
ized anticancer strategy could be fundamental as both
could integrate patient- and tumor-associated achieve-
ments in research in an adoptable and cost sensitive
manner.
Support
The manuscript was supported by the Theodor-Billroth-
Academy® (TBA®) and INCORE, (International Consor-
tium of Research Excellence) of the (TBA®).
Abbreviations
AJCC: American Joint Committee on Cancer; ASCO: American Society of
Clinical Oncology; CCR: Colorectal carcinoma; CML: Chronic myelogenous
leukaemia; QL: Quality in life; SNP: Single nucleotide polymorphisms;
UICC: International Union Against Cancer.
Competing interests
No author has something to disclose or competing existing interests.
Authors’ contributions
This manuscript contains original material that has not been previously
published. The content of the manuscript are discussions with each single
author over a 10-year time period. All authors contributed in discussing the

































1Theodor-Billroth-Academy®, Munich, Germany. 2Theodor-Billroth-Academy®,
Sacramento, CA, USA. 3Theodor-Billroth-Academy®, Richmond, VA, USA.
4INCORE, International Consortium of Research Excellence of the Theodor-
Billroth-Academy®, Munich, Germany. 5INCORE, International Consortium of
Research Excellence of the Theodor- Billroth-Academy®, Sacramento, CA,
USA. 6INCORE, International Consortium of Research Excellence of the
Theodor- Billroth-Academy®, Richmond, VA, USA. 7Bon Secours Cancer
Institute, Richmond, VA, USA. 8Fred Hutchinson Cancer Research Center,
University of Washington, Seattle, WA, USA. 9Department of Surgery,
University Medical Center, Utrecht, The Netherlands. 10Surgical Oncology,
Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
11Medical Oncology, University of Leipzig, Leipzig, Germany. 12Department of
Surgery, Seoul National University Hospital, Seoul, Korea. 13Division of
Epigenomics, National Cancer Center Research Institute, Tokyo, Japan. 14Yong
Loo Lin School of Medicine, National University of Singapore, Singapore,
Singapore. 15Department of Surgery, Masaryk University, Brno, Czech
Republic. 16Surgery, Medical University of Lublin, Lublin, Poland. 17The
Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam,
The Netherlands. 18Institutio Nazionale Tumori Regina Elena, Roma, Italy.
19Department of Surgery, Catholic University Rome A, Rome, Italy. 20Surgical
Oncology, University of Siena, Siena, Italy. 21University of Essen, Essen,
Germany. 22Sylvia Lawry Center for MS Research, Munich, Germany.
23Biochemistry and Molecular Biology, Georgia Regents University, Augusta,
GA, USA. 24Regional Cancer Center Memorial Hospital of South Bend, South
Bend, IN, USA. 25Departement of Medicine, Institut Gustave Roussy, Villejuif,
Universite Paris-Sud, Le Kremlin, Bicetre, France. 26Department of Surgery,
Keio University, Tokyo, Japan. 27National Center for Cancer Care and
Research, Doha, Qatar. 28Digestive Surgery Division, Sao Paulo University, San
Paulo, Brazil. 29Department of Surgery, Madigan Army Medical Center,
Tacoma, WA, USA. 30Risk-based Decisions Inc, Sacramento, CA, USA.
Received: 7 November 2013 Accepted: 7 March 2014
Published: 14 March 2014References
1. Kohane IS, Drazen JM, Campion EW: A Glimpse of the next 100 years in
Medicine. N Engl J Med 2012, 367(26):2358–2539.
2. Schultz M, Parzinger H, Posdnjakov DV, Chikicheva TA, Schmidt-Schultz TH:
Oldest known case of metastasizing prostate carcinoma diagnosed in
the skeleton of a 2,700-year-old Scythian King from Arzhan (Siberia,
Russia). Int J Cancer 2007, 121(12):2591–2595.
3. Cunha F: The Edwin Smith surgical papyrus. Am J Surg 1949, 77(6):793–795.
4. Breasted JH: Historical tradition and oriental research. Proc Natl Acad Sci
1924, 10(15):289–294.
5. Shimkin MB: Contrary to Nature. Washington D.C.: U.S: Department of
Health, Education and Welfare; 1977.
6. Novinsky M: Zur Frage ueber die Impfungen der Krebsigen
Geschwuelste. Centralbl f d Wissenschaften 1876, 14:790–791.
7. Sobin LH, Gospodarowicz MK, Wittekind C: TNM classification of malignant
tumors, Volume 7. Oxford: Wiley-Blackwell; 2010.
8. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the
Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971,
31(11):1860–1861.
9. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC,
Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened
to discuss the evaluation and staging of patients with Hodgkin's disease:
Cotswolds meeting". J Clin Oncol 1989, 7(11):1630–1636.
10. Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, Briganti A,
Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F: Biopsy core
number represents one of foremost predictors of clinically significant
gleason sum upgrading in patients with low-risk prostate cancer. Urology
2009, 73(5):1087–1091.11. Cohen N, Kravchenko-Balasha N, Klein S, Levitzki A: Heterogeneity of gene
expression in murine squamous cell carcinoma development – the same
tumour by different means. PLoS ONE 2013, 8(3):e57748.
12. Druker BJ: Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic
strategy for CML. Oncogene 2002, 21(56):8541–8546.
13. Von Bubnoff N, Scheller F, Peschel C, Duyster J: BCR-ABL gene mutations
in relation to clinical resistance of Philadelphia-chromosome-positive
leukaemia to DTI571: a prospective study. Lancet 2002, 359(9305):487–491.
14. Accelerating Progress Against Cancer: ASCO’s Blueprint for Transforming Clinical
and Translational Research. http://www.asco.org/sites/default/files/
blueprint.pdf.
15. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA: Cancer mortality
surveillance—United States, 1990–2000. MMWR Surveill Summ 2004,
53:1–108.
16. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63(1):11–13.
17. Watson EK, Rose PW, Loftus R, Devane C: Cancer survivorship: the impact
on primary care. Br J Gen Pract 2011, 61(592):e763–e765.
18. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation.
Cell 2011, 144(5):646–674.
19. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control.
Nat Med 2004, 10(8):789–799.
20. Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A: Molecular biology in breast
cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012,
38(6):698–707.
21. Jones PA, Baylin SB: The epigenomics of cancer. Cell 2007, 128(4):683–692.
22. Buess M, Terracciano L, Reuter J, Ballabeni P, Boulay JL, Laffer U, Metzger U,
Herrmann R, Rochlitz C: Amplification of Ski is a prognostic marker in
early colorectal cancer. Neoplasia 2004, 6(3):207–212.
23. Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U,
Herrmann R, Rochlitz C: SMAD4 is a predictive marker for 5-fluorouracil-
based chemotherapy in patients with colorectal cancer. Br J Cancer 2002,
87(6):630–634.
24. Boulay J-L, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L, Laffer U,
Herrmann R, Rochlitz C: Smad 7 is a prognostic marker in patients with
colorectal cancer. Int J Cancer 2003, 104(4):446–449.
25. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J:
Randomized controlled trial of cetuximab plus chemotherapy for
patients with KRAS wild-type unresectable colorectal liver-limited
metastases. J Clin Oncol 2013, 31(16):1931–1938.
26. Kim JC, Kim SY, Cho DH, Ha YJ, Choi EY, Kim CW, Roh SA, Kim TW, Ju H, Kim
YS: Novel chemosensitive single-nucleotide polymorphism markers to
targeted regimens in metastatic colorectal cancer. Clin Cancer Res 2011,
17(5):1200–1209.
27. Kim JC, Ha YJ, Roh SA, Choi EY, Yoon YS, Kim KP, Hong YS, Kim TW, Cho DH,
Kim SY, Kim YS: Feasibility of proposed single-nucleotide polymorphisms as
predictive markers for targeted regimens in metastatic colorectal cancer.
Br J Cancer 2013, 108(9):1862–1869.
28. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC:
Metabolic phenotyping in clinical and surgical environments. Nature
2012, 491(7424):384–392.
29. Dudziec E, Goepe JR, Catto JW: Global epigenetic profiling in bladder
carcinoma. Epigenomics 2011, 3(1):34–45.
30. Bensinger SJ, Christofk HR: New aspects of the Warburg effect in cancer
cell biology. Semin Cell Dev Biol 2012, 23(4):352–361.
31. DeBernadinis RJ, Lum JJ, Hatzivassilou G, Thompson CB: The biology of
cancer: metabolic reprogramming fuels cell growth and proliferation.
Cell Metabolism 2008, 7(1):11–20.
32. Brücher BLDM, Swisher S, Konigsrainer H, Zieker D, Hartmann J, Stein H,
Kitagawa Y, Law S, Ajani JA: Response to preoperative therapy in upper
gastrointestinal cancers. Ann Surg Oncol 2009, 16(4):878–886.
33. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F,
Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ,
Siegel PM, Jones RG: AMPK is a negative regulator of the Warburg effect
and suppresses tumor growth in vivo. Cell Metab 2013, 17(1):113–124.
34. Yaffee MB: The scientific drunk and the lamppost: massive sequencing
efforts in cancer discovery and treatment. Sci Signal 2013, 6(269):e13.
35. Honda K, Ono M, Shitashige M, Masuda M, Kamita M, Miura N, Yamada T:
Proteomic approaches to the discovery of cancer biomarkers for early
detection and personalized medicine. Jpn J Clin Oncol 2013,
43(2):103–109.
Brücher et al. BMC Cancer 2014, 14:186 Page 8 of 8
http://www.biomedcentral.com/1471-2407/14/18636. Zhou W, Liotta LA, Petricoin EF: Cancer metabolism: what we can learn
from proteomic analysis by mass spectrometry. Cancer Genomics
Proteomics 2012, 9(6):373–381.
37. Leung F, Diamandis EP, Kulasingam V: From bench to bedside: discovery
of ovarian cancer biomarkers using high-throughput technologies in the
past decade. Biomark Med 2012, 6(5):613–625.
38. Grivennikov SI, Greten FR, Karin M: Immunity, Inflammation, and Cancer.
Cell 2010, 140(6):883–899.
39. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF,
Karin M: IKKβ links inflammation and tumorigenesis in a mouse model of
colitis-associated cancer. Cell 2004, 118(3):285–296.
40. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E,
Urieli-Shoval S, Galun E, Ben-Neriah Y: NF-κB functions as a tumour promoter
in inflammation-associated cancer. Nature 2004, 431(7007):461–466.
41. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G,
Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G:
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
N Engl J Med 2003, 348(3):203–213.
42. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL,
Freeman SM: Study of tumor infiltrating lymphocytes and transforming
growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer
1997, 74(5):492–501.
43. Vesalainen S, Lipponen P, Talja M, Syrjanen K: Histological grade, perineural
infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants
of long-term prognosis in prostatic adenocarcinoma. Eur J Cancer 1994,
30A(12):1797–1803.
44. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y,
Shintaku I, Nagura H, Ohtani H: Proliferative activity of intratumoral CD8
(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma:
clinicopathologic demonstration of antitumor immunity. Cancer Res
2001, 61(13):5132–5136.
45. Schumacher K, Haensch W, Roefzaad C, Schlag PM: Prognostic significance
of activated CD8(+) T cell infiltrations within esophageal carcinomas.
Cancer Res 2001, 61(10):3932–3936.
46. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H: CD8+ T
cells infiltrated within cancer cell nests as a prognostic factor in human
colorectal cancer. Cancer Res 1998, 58(16):3491–3494.
47. Halpern AC, Schuchter LM: Prognostic models in melanoma. Semin Oncol
1997, 24(Suppl4):S2–S7.
48. Kawalec P, Paszulewic A, Holko P, Pilc A: Sipuleucel-T immunotherapy for
castration-resistant prostate cancer. A systematic review and meta
analysis. Arch Med Sci 2012, 8(59):767–775.
49. Wilginhof S, Four SD, Vandenbroucke F, Everaert H, Salmon I, Liénard D,
Marmol VD, Neyns B: Single-center experience with ipilimumab in an
expanded access program for patients with pretreated advanced
melanoma. J Immunother 2013, 36:215–222.
50. Yamanaka S: Induced pulripotent stem cells: past, present, and future.
Cell Stem Cell 2012, 10(6):678–684.
51. Hanna JH, Saha K, Jaenisch R: Pluripotency and cellular programming:
facts, hypotheses, unresolved issues. Cell 2010, 143(4):508–525.
52. Hulsegge G, Susan H, Picavet J, Nooyens AC, Spijkerman AM, van der
Schouw YT, Smit HA, Verschuren WM: Today's adult generations are less
healthy than their predecessors: generation shifts in metabolic risk
factors: the doetinchem cohort study. Eur J Prev Cardiol 2013: Apr 15
[Epub ahead of print]
53. Galway K, Black A, Cantwell M, Cardwell CR, Mills M, Donnelly M:
Psychosocial interventions to improve quality of life and emotional
wellbeing for recently diagnosed cancer patients. Cochrane Database Syst
Rev 2012, 11, CD007064.
54. Graham J, Ramirez A, Love S, Richards M, Burgess C: Stressful life
experiences and risk of relapse of breast cancer: observational cohort
study. BMJ 2002, 324(7351):1420.
55. Chida Y, Hamer M, Wardle J, Steptoe A: Do stress-related psychosocial
factors contribute to cancer incidence and survival? Nature Clinical
Practice Oncology 2008, 5(8):466–475.
56. Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner
NL, Munoz SA, Zijlstra A, Yang X, Sterling JA, Elefteriou F: Stimulation of
host bone marrow stromal cells by sympathetic nerves promotes breast
cancer bone metastasis in mice. PLoS Biol 2012, 10(7):e1001363.
57. Balboni MJ, Sullivan A, Amobi A, Phelps AC, Gorman DP, Zollfrank A, Peteet
JR, Prigerson HG, Vanderweele TJ, Balboni TA: Why is spiritual careinfrequent at the end of life? Spiritual care perceptions among patients,
nurses, and physicians and the role of training. J Clin Oncol 2013,
31(4):461–467.
58. Shah MA, Kelsen DP: Gastric cancer: a primer on the epidemiology and
biology of the disease and an overview of the medical management of
advanced disease. J Natl Compr Canc Netw 2010, 8(4):437–447.
59. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens
P, Stalmeier PF, ten Kate FJ, van Dekken H, Obertop H, Tilanus HW, van
Lanschot JJ: Extended transthoracic resection compared with limited
transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med
2002, 347(21):1662–1669.
60. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ,
Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE,
Verma M, Weeden S, Chua YJ, MAGIC Trial Participants: Perioperative
chemotherapy versus surgery alone for resectable gastroesophageal
cancer. N Engl J Med 2006, 355(1):11–20.
61. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer
treatment. Cancer 1981, 47(1):207–214.
62. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG:
New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst 2000, 92(3):205–216.
63. James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P:
Measuring response in solid tumors: unidimensional versus bidimensional
measurement. J Natl Cancer Inst 1999, 91(6):523–528.
64. Brücher BLDM, Bilchik A, Nissan A, Avital I, Stojadinovic A: Tumor response
criteria: are they appropriate? Future Oncology 2012, 8(8):903–906.
65. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S,
Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel
C, Schwaiger M, Siewert JR: PET to assess early metabolic response and to
guide treatment of adenocarcinoma of the oesophagogastric junction:
the MUNICON phase II trial. Lancet Oncol 2007, 8(9):797–805.
66. National Cancer Institute: General cancer prevention information. Website
National Cancer Institute 2013. http://www.cancer.gov/cancertopics/
prevention.
67. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW:
Cancer genome landscapes. Science 2013, 339(6127):1546–1558.
68. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57–70.
69. Parkin DM: The global health burden of infection-associated cancers in
the year 2002. Int J Cancer 2006, 118(12):3030–3044.
70. Xia JJ, Gulati R, Au M, Gore JL, Lin DW, Etzioni R: Effects of screening on
radical prostatectomy efficacy: the prostate cancer intervention versus
observation observation trial. J Natl Cancer Inst 2013, 105(8):546–550.
71. Steevens J, Schouten LJ, Driessen AL: Toenail selenium status and the risk
of Barrett's esophagus: the Netherlands Cohort Study. Cancer Causes
Control 2010, 21(12):2259–2268.
72. Van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA: Toenail selenium
levels and the subsequent risk of prostate cancer: a prospective cohort
study. Cancer Epidemiol Biomarkers Prev 2003, 12(9):866–871.




Cite this article as: Brücher et al.: Imagine a world without cancer. BMC
Cancer 2014 14:186.
